MINERVA NEUROSCIENCES INC (NERV)

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-06-25. The firm is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The firm's lead product candidates are roluperidone (MIN-101) and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The firm is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The Company’s MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders. The firm is also developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD).

Company Info

MINERVA NEUROSCIENCES INC

1601 Trapelo Road, Suite 284

Waltham MASSACHUSETTS 02451

P: 16176007373

CEO: Remy Luthringer

Employees: 9

Website: https://www.minervaneurosciences.com/